Syneron's elure Brings Home Allure Magazine's Best of Beauty Award, for the Third Consecutive Year

IRVINE, California, September 17, 2013 /PRNewswire/ --

Syneron Medical (NASDAQ: ELOS), http://www.syneron.com, the global leader in medical aesthetic products and technology, announced that Allure magazine has named elure™ Advanced Lightening Lotion in their Best of Beauty Awards, to be published in the October 2013 issue.

     (Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

Allure, the first and only magazine devoted to beauty, identifies the most effective and innovative products on the market today in their annual Best of Beauty Awards. Among thousands of products that are considered each year, elure™ Advanced Lightening Lotion was named in the Best of Beauty: Skin Care category as the one of the best anti-ager for skin discoloration. The magazine noted that elure™ Advanced Lightening Lotion containing a mushroom-derived enzyme, "diminishes discoloration in four weeks without irritating hydroquinone."

"To be named once again in this prestigious list for the third consecutive year is a testament of elure's proven effectiveness in diminishing discoloration and brightening skin safely and successfully," says Dr. Shimon Eckhouse, CEO and co-founder of Syneron. "We are very pleased that the beauty editors at Allure have shown such unprecedented support for the elure brand, and we are proud that this recognition adds to elure's growing list of awards in the nation's leading beauty and skincare magazines."

elure™ Advanced Brightening Lotion is now available in a new 45 mL size, which is 50% more volume than the original best-seller

The lotion contains the patented technology Melanozyme™ - a formulation derived from a naturally occurring mushroom enzyme that works to brighten skin safely and effectively. Melanozyme™ breaks up existing discoloration without the irritation and side effects of harsh prescription skincare that primarily works to stop pigment formation such as hydroquinone and many other leading cosmeceuticals.

A noticeable change in skin's radiance, texture, tone and overall appearance can be seen in as little as four weeks, with best results seen in eight to twelve weeks.

The October issue of Allure hits newsstands on September 17.

See what Allure had to say about elure™ Advanced Lightening Lotion at:

http://www.allure.com/beauty-products/best-of-beauty/2013/best-of-beauty-skin-care#slide=11

For more information about elure's full range of products visit http://www.elureskin.com or follow us on Facebook: http://www.facebook.com/elureskin.

About Syneron Medical Ltd.

Syneron Medical Ltd. - a company devoted to real technology, real science and real results - is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. With its innovative approach to aesthetic treatments, Syneron has now entered into one of the largest in-demand applications, skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

elure™ is sold as a topical cosmetic intended to beautify your skin and cosmetics are not subject to evaluation by FDA in the US . All product information provided is intended to be for informational purposes only. The information about skin conditions provided herein does not constitute medical or pharmaceutical advice and should not be relied upon as a substitute for qualified medical consultation with health professionals.

Additional information can be found at http://www.syneron.com.

Contacts:

Melissa Kelz Communications, Inc. - +1-646-450-5359
Melissa - melissa@kelzpr.com  
Patty - PattyMathews@kelzpr.com
Syneron PR - pr@syneron.com

Hugo Goldman
Chief Financial Officer
Hugo.Goldman@syneron.com

SOURCE Syneron Medical Ltd.